Skip to main content
Serina Therapeutics, Inc. logo

Serina Therapeutics, Inc. — Investor Relations & Filings

Ticker · SER ISIN · US00848H1086 LEI · 5493005PJ4B0GQ36ED85 US Manufacturing
Open in API
Filings indexed 474 across all filing types
Latest filing 2025-11-26 Director's Dealing
Country US United States of America
Listing US SER

About Serina Therapeutics, Inc.

https://serinatherapeutics.com/

Serina Therapeutics, Inc. is a biotechnology company that develops novel therapeutics based on its proprietary POZ platform technology. This platform utilizes advanced polyoxazoline (POZ) polymers to create drug delivery systems for small molecule drugs, aiming to improve their therapeutic properties, safety, and efficacy. The technology is designed for programmable and targeted drug delivery to optimize treatments. The company's development pipeline is focused on addressing unmet medical needs in neurological diseases, including Parkinson's disease, as well as pain, cancer, and inflammation. Serina Therapeutics aims to redefine the standard of care by enhancing the performance of new and existing drug candidates.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2025-11-26 English
FORM 4
Director's Dealing
2025-11-19 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Serina Therapeutics, Inc. It specifically states that it is furnishing a press release announcing financial results for the quarter ended September 30, 2025. The document itself does not contain detailed financial statements or substantive financial data but rather references the press release as Exhibit 99.1. The length of the document is 3522 characters, which is relatively short and consistent with an announcement rather than a full financial report. According to the rules, such a document that announces or furnishes a press release of financial results without containing the full report should be classified as a Regulatory Filing (RNS) rather than an Earnings Release (ER) or Interim Report (IR).
2025-11-13 English
10-Q
Interim / Quarterly Report Q3 2025
2025-11-13 English
FORM 4
Director's Dealing
2025-11-12 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated November 7, 2025, reporting the results of the company's 2025 Annual Meeting of Stockholders. It includes detailed voting results for director elections, auditor ratification, and approval of a convertible note and warrants proposal. The key section is 'Item 5.07 Submission of Matters to a Vote of Security Holders,' which clearly indicates this is an official declaration of voting results from a shareholder meeting. The document is about the voting outcomes, not the meeting materials or the annual report itself. The length is 4213 characters, which is relatively short and consistent with a voting results announcement. Therefore, the appropriate classification is Declaration of Voting Results & Voting Rights Announcements (DVA).
2025-11-12 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.